Physician profile
William E Miller
NPI 1669434874
$620.48
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $107.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $177.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $104.35 | 2019-2020 | |
| Incyte Corporation | $82.35 | 2019 | |
| Verastem, INC. | $49.65 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.75 | 2019 | |
| Alexion Pharmaceuticals, INC. | $40.65 | 2019-2020 | |
| Seagen INC. | $34.91 | 2019 | |
| Astellas Pharma US INC | $19.91 | 2020 | |
| Agios Pharmaceuticals, INC. | $18.10 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.42 | 2019 | |
| Pfizer INC. | $16.24 | 2019 | |
| Dova Pharmaceuticals | $15.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.